Podcast
OncLive® On Air
Hosted by OncLive® On Air · EN
In OncLive® On Air, you can expect to hear interviews with academic oncologists on the thought-provoking oncology presentations they give at the OncLive® State of the Science Summits. The topics in oncology vary, from systemic therapies, surgery, radiation therapy, to emerging therapeutic approaches in a particular type of cancer. This includes lung cancer, breast cancer, gastrointestinal cancers, hematologic malignancies, gynecologic cancers, genitourinary cancers, and more.
91episodes
Episodes
Newest firstAll episodes
S17 Ep43: FDA Approval Insights: T-DXd for Early-Stage HER2+ Breast Cancer: With Charles E. Geyer, MD
2w ago00:19:20Tap to summarizeIn today’s episode, we welcomed Charles E. Geyer, MD, to discuss recent FDA approvals of fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) for the management of HER2-positive breast cancer. Dr Geyer is a professor of medicine and chief of Malignant Hematology and Medical Oncology in the Department of Medicine at the University of Pittsburgh and the University of Pittsburgh Medical Center Hillman Cancer Center in Pennsylvania.On May 15, 2026, the FDA approved T-DXd for the neoadjuvant treatment of adult patients with HER2-positive stage II or III breast cancer, as determined by an FDA-authorized test, followed by a taxane, trastuzumab (Herceptin), and pertuzumab (Perjeta); the regulatory agency simultaneously approved post-neoadjuvant T-DXd for the treatment of adult patients with HER2-positive breast cancer who have residual invasive disease after neoadjuvant HER2-targeted treatment.In our exclusive interview, Dr Geyer discussed the significance of these approvals, key data from the pivotal trials, and how these new indications for T-DXd are shaking up the HER2-positive breast cancer treatment paradigm.
Transcribe →
S17 Ep42: Treatment Intensification in Vulnerable Populations: ARPI Use in Elderly, Frail, and High-Comorbidity Patients With mCSPC: With Martin Schoen, MD, and Andrew W. Hahn, MD
2w ago00:38:47Tap to summarizeIn today’s episode, we spoke with Martin Schoen, MD, and Andrew W. Hahn, MD. Dr Schoen is a hematologist/oncologist and hospitalist at St. Louis Veterans Affairs Medical Center and Assistant Professor of Medicine at Saint Louis University. Hahn is an assistant professor in the Department of Genitourinary Medical Oncology at The University of Texas MD Anderson Cancer Center.In our exclusive interview, Drs Schoen and Hahn discussed the clinical evidence for androgen receptor pathway inhibitors (ARPIs), including enzalutamide, in patients with de novo metastatic castration-sensitive prostate cancer (mCSPC) who are elderly, frail, or have a high comorbidity burden. They also highlighted findings from a subgroup analysis the Veterans Affairs dataset evaluating outcomes with androgen deprivation therapy plus ARPIs in high-comorbidity, frail, and elderly patients with high-volume mCSPC.
Transcribe →
S17 Ep41: Dissecting INDEPENDENCE Data and the Role of Luspatercept in Myelofibrosis-Associated Anemia: With Claire Harrison, MD
2w ago00:11:10Tap to summarizeIn today’s episode, we welcomed Claire Harrison, MD, a professor of myeloproliferative neoplasms and clinical director at Guy's and St Thomas' NHS Foundation Trust in London, United Kingdom.In the exclusive interview, Dr Harrison discussed management strategies for anemia in patients with myelofibrosis and the implications of the phase 3 INDEPENDENCE trial (NCT04717414) presented at the 2026 EHA Congress. Dr Harrison detailed the prevalence and current challenges in managing myelofibrosis-associated anemia. She also detailed key efficacy outcomes reported for luspatercept-aamt (Reblozyl) in the INDEPENCENCE study, along with outlining some of the factors that contributed to the study narrowly missing statistical significance for its primary end point of red blood cell transfusion independence for at least 12 consecutive weeks during the first 24 weeks of treatment.
Transcribe →
S17 Ep44: SERENA-6 Splits the Breast Cancer Field on Switching Therapy Before Radiographic Progression: With Sara Nunnery, MD, MSCI; and Megan Kruse, MD
2w ago00:45:14Tap to summarizeNo description available
Transcribe →
S17 Ep40: Medical Crossfire®: Turning Therapeutic Innovation Into Practice—Personalizing Care in Multiple Myeloma
2w ago00:30:46Tap to summarizeIn this podcast, experts Philippe Moreau, MD; Suzanne Lentzsch, MD, PhD; and Shaji Kumar, MD, discuss therapeutic innovations in the treatment of multiple myeloma, including frontline quadruplet therapy, administration considerations for therapy, and optimal sequencing of CAR T-cell therapy, bispecific antibodies, and antibody-drug conjugates.To learn more about this topic, including information on future directions in MM and audience Q&A, go to https://www.gotoper.com/courses/medical-crossfire-turning-therapeutic-innovation-into-practicepersonalizing-care-in-multiple-myeloma-p2f5.This podcast, including the narration, was developed by PER® editorial staff based on an online CME activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool.
Transcribe →
S17 Ep39: Sequencing and Emerging Targets Revamp the Platinum-Resistant Ovarian Cancer Treatment Paradigm: With David O’Malley, MD
2w ago00:17:55Tap to summarizeIn today’s episode, we spoke with David O’Malley, MD. Dr O’Malley is a professor in the Department of Obstetrics and Gynecology at The Ohio State University College of Medicine and the director of the Division of Gynecologic Oncology at The Ohio State University Comprehensive Cancer Center–James in Columbus, Ohio. In our exclusive interview, Dr O’Malley discussed his approach to treatment selection and sequencing in platinum-resistant ovarian cancer, a disease setting he described as representing the highest unmet need in the field. He emphasized the central role of clinical trial enrollment and biomarker-driven decision-making, alongside practical patient-centered considerations, such as infusion schedule and quality of life.He highlighted the growing importance of antibody-drug conjugates (ADCs) in this setting, noting that folate receptor alpha and HER2 are the two biomarkers most relevant to current practice. Dr O’Malley outlined how National Comprehensive Cancer Network guidelines support treatment across a broader range of expression levels than initial approvals reflected, citing emerging data suggesting activity even at lower expression thresholds. He also addressed payload sequencing, explaining that outside of a clinical trial, he currently uses topoisomerase I–based ADCs and antimicrotubule-based ADCs each one time only, and remains open to targeting the same antigen again if the payload differs.The discussion also touched on combination strategies, resistance biology, and the evolving role of immunotherapy following the survival benefit observed with pembrolizumab (Keytruda) in the phase 3 KEYNOTE-B96 trial (NCT05116189). Dr O’Malley expressed enthusiasm for next-generation payloads, dual-target approaches, and the potential for bispecific antibodies and novel DNA damage response–targeting agents to define the post-ADC treatment landscape.Finally, Dr O’Malley underscored the need for more tumor biopsies to better characterize resistance mechanisms and called for expanded pharmaceutical investment in retreatment and cross-resistance studies to guide future sequencing decisions.
Transcribe →
S17 Ep38: FDA Approval Insights: Decitabine/Cedazuridine Plus Venetoclax for AML: With Courtney D. DiNardo, MD, MSCE
2w ago00:10:04Tap to summarizeIn today’s episode, we spoke with Courtney D. DiNardo, MD, MSCE, a professor in the Department of Leukemia in the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center and an associate member of The University of Texas Graduate School of Biomedical Sciences in Houston.In our exclusive interview, Dr DiNardo discussed the May 2026 FDA approval of decitabine (Dacogen) and cedazuridine (Inqovi) plus venetoclax (Venclexta) in patients with newly diagnosed acute myeloid leukemia (AML). DiNardo outlined numerous important facets of the approval, including its effects on the treatment paradigm, which patients will benefit most, safety considerations with the regimen, and quality of life advantages that have been observed with the combination. Furthermore, she discussed how this approval fits into a larger shift for the AML treatment paradigm and how the AML research field can build upon the approval of this regimen.
Transcribe →
S17 Ep37: Live Tumor Board: Translating Biomarker Insights and Therapeutic Advances Into Endometrial Cancer Practice
2w ago00:35:09Tap to summarizeIn this podcast, experts Kathleen N. Moore, MD, MS, FASCO; Ritu Salani, MD, MBA; Casey Cosgrove, MD; and Ebony R. Hoskins, MD, FACOG, discuss several cases of endometrial cancer using biomarkers to drive treatment decisions.
Transcribe →
S17 Ep36: FDA Approval Insights: Orally Disintegrating Nilotinib Tablets for CML: With Michael J. Mauro, MD
3w ago00:09:33Tap to summarizeIn today’s episode, we spoke with Michael J. Mauro, MD, an attending physician at Memorial Sloan Kettering Cancer Center in New York, New York.In our exclusive interview, Dr Mauro discussed the orally disintegrating tablet formulation of nilotinib (Cavhanza) and its recent June 2026 FDA approval for patients with chronic myeloid leukemia (CML). After diving into the approval itself and the data that supported it, Mauro discussed why the approval is significant and which patients it will benefit most. In addition to covering the approval, Mauro shed light on what is to come for biosimilars and alternate formulations in the greater CML treatment paradigm.
Transcribe →
S17 Ep35: KRAS-Directed Therapy Enters a New Era in Pancreatic Cancer: With Zev A. Wainberg, MD
3w ago00:10:42Tap to summarizeIn this episode of OncLive On Air, Zev A. Wainberg, MD, sat down with OncLive to discuss the rapidly evolving landscape of KRAS-directed therapy in pancreatic ductal adenocarcinoma (PDAC), from pan-RAS inhibition to KRAS G12D–specific strategies, and what the next several years of clinical investigation may look like for patients with this difficult-to-treat malignancy. Wainberg is a professor of medicine at the David Geffen School of Medicine at UCLA, co-director of the UCLA GI Oncology Program, and medical director of the UCLA Pancreas Cancer Center, where he also serves as director of the Early Phase Clinical Research Program at the Jonsson Comprehensive Cancer Center. This content is a production of OncLive; this OncLive On Air podcast episode is supported by funding, however, content is produced and independently developed by OncLive
Transcribe →